Immunogen (IMGN) Tops Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. USO
3. BBIO
4. SPY
5. NVDA
6. OPCH
7. SKYD
8. GOOGL
9. AMD
10. STZ

Go back to Immunogen (IMGN) Tops Q4 EPS by 1c

ImmunoGen Reports Pipeline Progress and 2017 Operating Results

February 9, 2018 6:30 AM EST

Significant Operational and Financial Progress in 2017 with a Robust Set of Data and Events Expected in 2018

Mirvetuximab Soravtansine Phase 3 FORWARD I Trial to Complete Enrollment by Mid-Year; FORWARD II Combination Data to be Presented Throughout 2018

Novel ADC Pipeline Continues to Advance with Patients Enrolling in Phase 1 Study of IMGN632 and Phase 1 Data Presented at ASH for IMGN779

Conference Call to be Held at 8:00 a.m. ET Today

WALTHAM, Mass.--(BUSINESS WIRE)--... More